Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles.

Want to learn about the latest research and development of cell models in rare diseases? Then join this virtual panel discussion to hear from industry experts.

The Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.

The new LSD-like compounds activated the 5HT2a receptor, a receptor stimulated by serotonin, without causing hallucinations.

Potential uses for the study could include repairing spinal cord injuries and a range of other localised injection applications.